-
Stay Connected
Get the latest news on exciting speakers, workshops & learning opportunities at ISDE 2021.
Subscribe for Updates
Accurate staging is central to choosing treatment for oesophageal cancer. Endoscopic ultrasonography, commonly called EUS or endosonography, provides high-resolution images of the oesophageal wall and nearby lymph nodes, helping clinicians define local tumour invasion and assess regional spread.
For Australian teams, EUS findings sit within a broader pathway that may include gastroscopy, contrast-enhanced CT, FDG-PET/CT, pathology and multidisciplinary review. A patient in Sydney or Melbourne may move quickly through a tertiary cancer service, while someone in regional Queensland, Western Australia or the Northern Territory may need coordinated travel and telehealth support.
The oesophageal wall has recognisable ultrasound layers, allowing EUS to estimate how deeply a tumour has penetrated. This is particularly useful for distinguishing early disease confined to the mucosa or submucosa from lesions invading the muscularis propria or surrounding tissue.
EUS is strongest for local T staging. It can identify suspicious lymph nodes based on size, shape, borders and echogenicity, although appearance alone is imperfect. Fine-needle aspiration or fine-needle biopsy can add tissue confirmation, especially when a positive nodal result would change the treatment plan.
EUS is most valuable when local staging will influence management. Early lesions being considered for endoscopic resection require careful assessment of depth, ulceration and possible lymphovascular risk. For locally advanced disease, EUS can help establish a baseline before neoadjuvant chemotherapy or chemoradiotherapy.
It should generally be interpreted alongside CT and PET/CT rather than used in isolation. CT is useful for distant anatomy and complications, while PET/CT can reveal metabolically active disease beyond the regional field. In Australia, these results are commonly reviewed at a multidisciplinary meeting involving gastroenterology, radiology, surgery, medical oncology and radiation oncology.
A complete examination begins with careful review of the diagnostic gastroscopy, tumour location and biopsy results. The endosonographer should document the upper and lower tumour margins, distance from the incisors, relationship to the gastro-oesophageal junction and any stenosis that limits scope passage.
Water coupling and appropriate frequency selection improve contact and image quality. Radial EUS is useful for circumferential anatomical assessment, while linear EUS enables targeted sampling. When a node is sampled, the needle path should avoid traversing the primary tumour where feasible, reducing the risk of contamination and ensuring that the specimen answers the clinical question.
Inflammation, fibrosis, ulceration and treatment-related oedema can mimic malignant invasion. A bulky lesion may obscure the deeper wall layers, leading to over-staging, while microscopic extension beyond an apparently intact layer can be missed. Benign reactive nodes may appear suspicious, and small malignant nodes may look deceptively ordinary.
Strictures are another practical problem. Forceful passage risks perforation and may produce incomplete staging. In a patient with significant narrowing, staging may need to rely more heavily on cross-sectional imaging, or be repeated after initial treatment. Operator experience matters, and reports should state technical limitations clearly rather than presenting uncertain findings as definitive.
Sampling also has limitations. FNA or FNB can be non-diagnostic because of fibrosis, necrosis, scant cellularity or difficult access. A negative sample does not always exclude malignancy when the ultrasound pattern and clinical context remain concerning. If a treatment reaction creates an unrelated skin differential, a clinical reference resource may help support broader documentation, though it does not replace pathology or specialist review.
EUS staging should answer a practical question: will this result alter the next treatment decision? A suspicious regional node confirmed by biopsy may support neoadjuvant therapy, whereas a superficial lesion without high-risk features may be considered for endoscopic treatment. The final plan must account for histology, patient fitness, nutrition, symptoms and comorbidities.
Nutrition is especially important in Australian practice, where patients may be referred between public hospitals, private specialists and rural services. Dysphagia, weight loss and dehydration can delay therapy, so staging should be coordinated with dietitians and supportive-care teams. Emerging approaches, including localised treatment strategies, are discussed in research coverage of novel drug delivery, but these concepts remain distinct from routine EUS staging.
Clear reporting should include the tumour site, estimated T category, regional nodal findings, sampled targets, technical restrictions and confidence level. It should also identify features relevant to resectability, such as invasion of adjacent structures, while recognising that CT, PET/CT and operative assessment may revise the initial impression.
The key point to remember is that endosonography is a high-value local staging tool, not a standalone verdict: its accuracy depends on technique, tissue confirmation when needed, awareness of pitfalls and integration with the full multidisciplinary picture.